PT  - JOURNAL ARTICLE
AU  - ZHU Yunqi
AU  - Hu Yongxian
AU  - Wang Jiasheng
AU  - Zhao Xin
AU  - Chen Donghe
AU  - Zhang Yafei
AU  - Zhao Kui
TI  - Prognostic and predictive role of FDG PET-CT in Non-Hodgkin lymphoma patients treated with chimeric antigen receptor (CAR) T‑cell therapy
DP  - 2019 May 01
TA  - Journal of Nuclear Medicine
PG  - 1317--1317
VI  - 60
IP  - supplement 1
4099  - http://jnm.snmjournals.org/content/60/supplement_1/1317.short
4100  - http://jnm.snmjournals.org/content/60/supplement_1/1317.full
SO  - J Nucl Med2019 May 01; 60
AB  - 1317Background: CD19-targeting chimeric antigen receptor (CAR) T-cell therapy has shown great efficacy in patients with refractory/relapse non-Hodgkin lymphoma (NHL), but was associated with serious adverse effects such as cytokine release syndrome (CRS). It has been speculated that NHL baseline disease burden might affect clinical outcome and CRS, however, such assumption has not been explored in detail in previous studies. Metabolic tumor volume (MTV) and total lesion glycolysis (TLG), as measured by FDG PET-CT, are quantitative indicators of baseline tumor burden. Methods: In the present study, by using FDG PET-CT, we calculated baseline and post CAR T-cell-therapy MTV and TLG in 19 patients with NHL. Results: The median MTV was 72 cm3(range 0.02-1137.7 cm3) and the median TLG was 555.9 (range 0.011-8990.3). After a median follow-up of 5 (range 0-12) months, the overall response rate (ORR) was 79.0%. The baseline MTV and TLG did not have significant difference in patients with or without response (p=0.62 and 0.95, respectively). Cox-regression analysis did not find baseline MTV and TLG significantly associated with overall survival (p=0.67 and 0.45, respectively). Patients with mild and moderate CRS (Grade 0-2) had significantly lower MTV and TLG than those with severe CRS (Grade 3, 4) (p=0.008 for MTV comparison, p=0.011 for TLG comparison). Conclusions: Baseline disease burden is not associated with clinical outcome. Patients with higher baseline disease burden have more severe CRS.